Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-02-15 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于控股股东、实际控制人及其一致行动人部分股权质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder, actual controller, and their concerted actors. It details the number of shares pledged, pledge dates, pledgees, and the purpose of the pledge. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activities, which is a capital structure related update but specifically about share pledges by major shareholders. This fits best under the category of Major Shareholding Notification (MRQ) because it involves disclosure of significant share ownership and pledging changes by major shareholders. The document length is short (2199 characters), and it is not an announcement of a report publication but a direct disclosure. Therefore, the classification is MRQ with high confidence.
2019-02-15 Chinese
关于执行总裁辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's Executive President (执行总裁辞职的公告). It details the resignation date, the impact on the company, and related stock option information. There is no financial data, no mention of a report or meeting, and it concerns a change in senior management. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2019-02-01 Chinese
2018年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2018 annual performance forecast (业绩预告) for 康芝药业股份有限公司, covering the period from January 1, 2018 to December 31, 2018. It provides estimated net profit figures and explanations for the expected performance decline compared to the previous year. The document explicitly states that the financial data is unaudited and is a preliminary estimate, with final audited figures to be disclosed in the 2018 Annual Report. The document length is short (1361 characters) and it serves as a performance forecast announcement rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year before the full annual report is published. It is not the full Annual Report (10-K), nor an Audit Report (AR), nor a Report Publication Announcement (RPA) since it contains substantive financial estimates and explanations. Therefore, the best classification is Earnings Release (ER). FY 2018
2019-01-30 Chinese
关于全资子公司获得政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kangzhi Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary receiving government subsidy funds. It details the subsidy project, the amount received, the accounting treatment, and the impact on profits. The document is short (1138 characters) and serves as a formal disclosure of a specific event (government subsidy receipt) rather than a financial report or detailed analysis. It does not contain financial statements or comprehensive financial data. This fits the profile of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2019-01-15 Chinese
关于2018年股票期权预留授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the registration of reserved stock options granted under the company's 2018 stock option incentive plan. It details the approval procedures, allocation, exercise price, exercise periods, and performance conditions related to the stock options. The document is a formal public announcement about a specific corporate action related to stock options, not a full financial report, earnings release, or management discussion. It does not contain financial statements or comprehensive financial analysis. It is also not a proxy solicitation, voting results announcement, or a regulatory certification. The content fits best into a category related to capital or financing updates, as it concerns stock option grants which affect the company's capital structure and equity incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4039 characters, which is consistent with an announcement rather than a full report.
2018-12-26 Chinese
广东胜伦律师事务所关于公司2018年股票期权激励计划预留部分授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by Guangdong Shenglun Law Firm regarding the 2018 stock option incentive plan reserved portion grant matters of Kangzhi Pharmaceutical Co., Ltd. It discusses the legal compliance, approval, authorization, and conditions related to the stock option incentive plan. The document is a standalone legal opinion and does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a legal opinion on a specific corporate action related to stock options. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal opinion related to corporate governance and securities regulation, but does not fit into more specific categories like Board/Management Information or Capital/Financing Update since it is a legal opinion rather than a direct announcement of management changes or financing events.
2018-12-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.